Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses

This is a 6-visit, single-masked, multi-site, 2×3 crossover, randomized-controlled, dispensing clinical trial to evaluate visual acuity.

Study Overview

• Status: Completed
• Conditions: Presbyopia; Visual Acuity
• Intervention / Treatment: Device: INFUSE® One Day Multifocal; Device: ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens

• Study Type: Interventional
• Enrollment (Actual): 74
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Jacksonville, Florida, United States, 32256
      • VRC
    • Jacksonville, Florida, United States, 32218
      • Dr. James Weber & Associates, PA - City Square Blvd
    • Longwood, Florida, United States, 32779
      • Pearson Research Center, PA
    • Maitland, Florida, United States, 32751
      • Maitland Vision Center - North Orlando Ave
  • New York
    • Vestal, New York, United States, 13850
      • Sacco Eye Group
  • Ohio
    • Powell, Ohio, United States, 43065
      • Luxe Vision and Optical
  • Rhode Island
    • Warwick, Rhode Island, United States, 02888
      • Dr. David W. Ferris & Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Be at least 40 years of age and not greater than 70 years of age at the time of consent.
4. Own a wearable pair of spectacles if required for their distance vision.
5. Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 30 days or more duration).
6. Either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, monovision or multifocal contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
7. The subject's distance spherical equivalent refraction must be in the range of +1.00 to +4.00 or -1.00 D to -4.00 D in each eye.
8. The subject's refractive cylinder must be ≤0.75 D in each eye.
9. The subject's ADD power must be in the range of +0.75 D to +2.50 D.
10. The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Be currently pregnant or lactating.
2. Have any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
3. Have been diagnosed with diabetes.
4. Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This includes, but not be limited to, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
5. Have any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal surgery, etc.).
6. Have a history of amblyopia, strabismus or binocular vision abnormality.
7. Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids. See section 9.1 for further examples.
8. Be currently using any ocular medications with the exception of rewetting drops.
9. Have a history of herpetic keratitis.
10. Have a history of irregular cornea.
11. Have a history of pathological dry eye.
12. Have participated in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
13. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild, sibling of the employee or their spouse) of the clinical site.
14. Have any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein.
15. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
16. Have any current ocular infection or inflammation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test/Control/Control; Eligible subjects will be randomized into the Test/Control/Control sequence.	Device: INFUSE® One Day Multifocal; Test Lens; Device: ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens; Control Lens
Experimental: Control/Test/Test; Eligible subjects will be randomized into the Control/Test/Test sequence.	Device: INFUSE® One Day Multifocal; Test Lens; Device: ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens; Control Lens

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at distance (4 meters)	Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at distance (4 meters) using ETDRS Charts.	1-week follow-up
High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at intermediate (64 cm)	Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at intermediate (64 cm) using reduced Guillon-Poling charts.	1-week follow-up
High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at near (40 cm)	Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at near (40 cm) using reduced Guillon-Poling charts.	1-week follow-up

Collaborators and Investigators

• Sponsor: Johnson & Johnson Vision Care, Inc.
• Investigators: Study Director: Johnson & Johnson Vision Care, Inc. Clinical Trial, Johnson & Johnson Vision Care, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 24, 2025
• Primary Completion (Actual): September 20, 2025
• Study Completion (Actual): September 20, 2025

Study Registration Dates

• First Submitted: July 14, 2025
• First Submitted That Met QC Criteria: July 14, 2025
• First Posted (Actual): July 22, 2025

Study Record Updates

• Last Update Posted (Actual): June 5, 2026
• Last Update Submitted That Met QC Criteria: June 4, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors; Presbyopia
• Other Study ID Numbers: CR-6612

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes